Competence Center for the Diagnosis and Treatment of Pruritus, Clinic and Polyclinic for Skin Diseases, University Hospital of Münster, Germany.
J Dtsch Dermatol Ges. 2010 Feb;8(2):88-91. doi: 10.1111/j.1610-0387.2009.07213.x. Epub 2009 Sep 10.
Postherpetic neuralgia is a frequent adverse event in herpes zoster patients and difficult to treat. Conventional analgetic therapy often fails to reduce the burning pain transmitted by unmyelinated nerve fibers. These nerves express cannabinoid receptors which exert a role in modulation of nociceptive symptoms. Therefore, topical therapy with cannabinoid receptor agonist seems likely to suppress local burning pain.
In an open-labeled trial, 8 patients with facial postherpetic neuralgia received a cream containing the cannabinoid receptor agonist N-palmitoylethanolamine. The course of symptoms was scored with the visual analog scale.
5 of 8 patients (62.5 %) experienced a mean pain reduction of 87.8 %. Therapy was tolerated by all patients. No unpleasant sensations or adverse events occurred.
Topical cannabinoid receptor agonists are an effective and well-tolerated adjuvant therapy option in postherpetic neuralgia.
带状疱疹后神经痛是带状疱疹患者常见的不良反应，且难以治疗。常规镇痛治疗往往无法减轻无髓神经纤维传递的烧灼感。这些神经表达大麻素受体，在调节痛觉症状方面发挥作用。因此，大麻素受体激动剂的局部治疗似乎有可能抑制局部烧灼感。
在一项开放性试验中，8 例面部带状疱疹后神经痛患者接受了含有大麻素受体激动剂 N-棕榈酰乙醇胺的乳膏治疗。症状严重程度采用视觉模拟评分法进行评分。
8 例患者中有 5 例（62.5%）疼痛平均减轻 87.8%。所有患者均耐受治疗。未出现不愉快感觉或不良反应。
局部大麻素受体激动剂是带状疱疹后神经痛的一种有效且耐受良好的辅助治疗选择。
